Navigation Links
ITP in Medical News

3SBio Inc. Files for SFDA Approval for TPIAO Label Extension for the Treatment of ITP

SHENYANG, China, Jan. 20 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX ), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it filed on December 30, 2008 with the Chine...

Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP

SOUTH SAN FRANCISCO, Calif., Nov. 21 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that it will host a conference call with simultaneous webcast to discuss the results of its Phase 2 clinical study of R788, a novel, oral Syk kinase inhibitor, in patient...

AIM Health Group Inc. reports largest quarterly profit since going public and announces filing of financial results for the three months ended March 31, 2009 on SEDAR

...Infusion Services where we provide intravenous infusions and subcutaneous injections to patients suffering from rheumatoid arthritis, Crohn's disease, itp and other inflammatory diseases, (iii) Pharmaceutical Research services where we provide clinical research services in community and hospital based si...

Novel therapeutic approaches may improve patient outcomes in several platelet disorders

...ding symptoms, allowed for a reduction of baseline itp therapy, and reduced the use of rescue medications... stratified by splenectomy status, use of baseline itp medication, and platelets of less than or equal to... eltrombopag arm were able to stop or reduce other itp medication and required less rescue therapy compar...

PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL

...d platelet counts and reduced bleeding. "Chronic itp is a condition, which can have serious complicatio...atment of previously treated patients with chronic itp to increase platelet counts and reduce or prevent ...formation on investigational therapies for chronic itp patients. Two pivotal trials (one Phase III trial ...

Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research

...tis (RA), and related autoimmune disorders. Rigel's R788, oral syk kinase inhibitor, is expected to enter advanced Phase 2 clinical studies for RA and itp this year, and also a Phase 2 clinical study in systemic lupus erythematosus. In addition, Rigel's oral JAK3 inhibitor, R348, is currently in a Phase ...

Drug-based on MGH discovery may significantly improve treatment of dangerous blood disorder

...r, in the February 2 issue of The Lancet. Many itp patients have had to choose between no therapy or ...an be easily managed with a weekly injection. itp is a chronic disorder in which the immune system d...lood cells that help prevent bleeding. While some itp patients experience only increased bruising, other...

GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder

...let counts and reduce or prevent bleeding. Chronic itp is a disorder marked by increased platelet destruc...w to produce platelets. "Patients with chronic itp do not have a treatment option that offers the con...roved, PROMACTA may provide physicians and chronic itp patients with a new, convenient and effective opti...

Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders

...a (ITP) per ASH guidelines and baseline platelet counts <30,000/µL. Chronic itp is an autoimmune disorder in which patients produce antiplatelet autoantibo...hose receiving the placebo, and were able to reduce their use of concurrent itp therapies. -- RECORD1 is the first pivotal trial to demonstrate the eff...

Eltrombopag studied in Idiopathic Thrombocytopenic Purpura

...ng the largest ever clinical trial of its kind for itp patients, the Phase 2 study found that eltrombopag...bic millimeter) in more than 75 percent of chronic itp patients within two weeks -- compared to 11 percen...dy within one week could be very useful to chronic itp patients in need of short-term treatment," says th...
ITP in Medical Technology

Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients

SAN FRANCISCO, Dec. 8 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN ) today released updated results from the ongoing, open-label extension study of the long-term safety and efficacy of Nplate(TM) (romiplostim) in adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic IT...

GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP

PHILADELPHIA, Dec. 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK ) announced positive safety and efficacy results from RAISE (RAndomized placebo- controlled ITP Study with Eltrombopag), a Phase III study of PROMACTA(R) (eltrombopag) in adults with chronic immune (idiopathic) thrombocyto...

Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP

VIENNA, Austria, June 11, 2007 /PRNewswire/ -- GlaxoSmithKline plc announced results from an international, pivotal Phase III study of its investigational non-peptide oral platelet growth factor, PROMACTA(R) (eltrombopag olamine). Data from this study showed that PROMACTA at 50-75mg once daily res...

Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

...second line treatment for adult non-splenectomised itp patients where surgery is contra-indicated. ...rm treatment of this chronic disease. Chronic itp is a serious autoimmune disorder characterised by ...enia), which can lead to serious bleeding events. itp is recognised as an orphan disease by the European...

Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders

...ding symptoms, allowed for a reduction of baseline itp therapy, and reduced the use of rescue medications... stratified by splenectomy status, use of baseline itp medication, and platelets of less than or equal to... eltrombopag arm were able to stop or reduce other itp medication and required less rescue therapy compar...

Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union

...ion and avoids immune suppression in adult chronic itp patients," said Willard Dere, M.D., senior vice pr...ate were able to reduce or discontinue concomitant itp and emergency medications which are often not well...ion in this study is 65 weeks. About Adult itp In patients with ITP, platelets -- or bloo...

FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder

...al is a significant milestone for PROMACTA and the itp community, as PROMACTA is the first oral thrombopo...t week. "It is very important for chronic itp patients to have new treatment options to manage t...ing disease. In addition, many people with chronic itp are concerned about everyday activities for fear o...

GSK Update on FDA Review of Promacta(R) (Eltrombopag)

...ards the approval of eltrombopag in order to provide physicians and chronic itp patients with a novel option for treating this difficult disease. About P...first oral short-term treatment of previously treated patients with chronic itp to increase platelet counts and reduce or prevent bleeding. In the pivotal ...

FDA Grants Priority Review for PROMACTA(R) (eltrombopag)

...atment of previously treated patients with chronic itp to increase platelet counts and reduce bleeding. ... (MAA) for eltrombopag in the treatment of chronic itp in Europe in 2008 where it will be marketed as REV... induced thrombocytopenia. About ITP Chronic itp is a disorder marked by increased platelet destruc...

Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting

...e most common being headache (20%).(1) Chronic itp is a disorder characterized by low levels of plate...n estimated 200,000 individuals are diagnosed with itp in the U.S.(5) and a similar number in Europe. PRO...tain patients' platelet levels and alleviate their itp symptoms," said James B. Bussel, MD, director of t...
ITP in Medical Products

CEQ 8800 Genetic Analysis System

Description:... The CEQ 8800 features unique DNA sequencing reagents including linear polyacrylamide gel (LPA), coated capillaries, itp chemistry and cyanine-based infrared dyes- coupled with online denaturation. This results in less correction, ore meaningful raw data, and higher-qua...
Company:Beckman Coulter, Inc.

CEQ™ 8800 Genetic Analysis System

Description:... The CEQ 8800 features unique DNA sequencing reagents including linear polyacrylamide gel (LPA), coated capillaries, itp chemistry and cyanine-based infrared dyes- coupled with online denaturation. This results in less correction, ore meaningful raw data, and higher-qua...
Company:Beckman Coulter, Inc.
ITP in Medical Definition

Hematopathology

... Hemochromatosis Coagulation / platelets DIC • Hemophilia ( A , B , C ) • Von Willebrand disease • Purpura ( Henoch-Schönlein , itp , TTP ) other Methemoglobinemia - Langerhans cell histiocytosis ...

Pathology

... Hemochromatosis Coagulation / platelets DIC • Hemophilia ( A , B , C ) • Von Willebrand disease • Purpura ( Henoch-Schönlein , itp , TTP ) other Methemoglobinemia - Langerhans cell histiocytosis v • d • e Endocrine pathology : endo...
ITP in Medical Dictionary

Itp

Idiopathic thrombocytopenic purpura ( ITP ) is the condition of having a low platelet count of no known cause (idiopathic). As most causes appear to be related to antibodies against platelets, ITP is also known as immune thrombocytopenic purpura or immune-mediated... Providing news, p...

Pediatrics

...ent today. ... Leonard M. Miller School of Medicine. Department of. Pediatrics ... Masters of Pediatrics Conference. Coagulation Disorders and itp symposium. Our Community ... Department of Pediatrics at the University of Colorado Denver School of Medicine, ... Department of Pediatrics · ...

Idiopathic

... the condition of having a low platelet count of no known cause ( idiopathic ). As most causes appear to be related to antibodies against platelets, itp is also known as immune thrombocytopenic purpura or immune-mediated... " Idiopathic Dilated Cardiomyopathy" is more commonly referred to as "...

Bleeding into the skin

...parent reason ... ... bruising, bleeding into the skin (petechiae) and often bleeding from mucous ... A rare but serious complication of itp is bleeding into the head. ... Aside from the common bruise, bleeding into the skin or mucous membranes is a ... You have sudden bl...
ITP in Biological News

Lancet study supports new, highly effective treatment for blood disorder

...nd older, with at least six months of history with itp and with low-platelet counts of 30,000 per microli...shown that the drug boosts platelet counts in both itp and normal subjects. Ongoing and future studies...et antibodies accelerate destruction of platelets. itp patients commonly have platelet counts of less tha...
ITP in Biological Technology

3SBio Inc. Announces Third Quarter 2008 Results

... a new treatment option for those cancer patients who have exhausted their options. Additionally, we remain on track with our SFDA submission of TPIAO itp by the end of 2008. I am confident that these enhancements to our pipeline and diversification to our product portfolio will not only enhance future r...

Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23

...rks by raising and sustaining platelet counts, representing a novel approach for the treatment of this chronic disease. Nplate was also approved for itp by Australia's Therapeutic Goods Administration (TGA) in July 2008. Amgen has filed for regulatory approval of Nplate in the European Union (EU), Cana...
Other Tags
(Date:5/24/2015)... New York, New York (PRWEB) May 24, 2015 ... of testosterone treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) has ... discuss the progress of the multidistrict litigation. According ... Court, Northern District of Illinois, the Conference will ... p.m. (In re: Testosterone Replacement Therapy Product Liability ...
(Date:5/24/2015)... 2015 Medicx Media Solutions ... executive Jay Krihak as its head of programmatic ... up its expertise and leadership position in the ... Health sectors. , Krihak is an experienced, award-winning ... Krihak led sales planning teams for mobile platform ...
(Date:5/23/2015)... Florida City, FL (PRWEB) May 23, 2015 ... together to build a new playground for Branches Florida City ... destroyed the former play space in 2010. , A large ... then new playground on May 23, 2010 in the middle ... families watched. The fire was later declared arson even though ...
(Date:5/23/2015)... 23, 2015 With the implementation of ... finding it increasingly difficult to provide their employees with ... provide adequate insurance for employees stand to face strict ... an integral part of a business’s success or failure. ... businesses, Online USA Doctors has created a varying level ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 Manufacturers are now ... Performance Factor (HSPF) of 8.2. Experts in the field agree ... benefit consumers. , The HSPF score is what miles per ... more efficient the unit. Although the minimum HSPF score has ... heaters with an HSPF score north of 12. Indeed, the ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Medicx Media Solutions Expands Executive Team 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
Other Contents